Hyderabad & Telangana
Hyderabad's NATCO Pharma Raises Investment in Pig-Organ Transplant Firm eGenesis to $16.7 Million
The additional commitment takes NATCO's total investment in the US xenotransplantation company to $24.7 million.
Drug development, manufacturing, regulation and life sciences.
The additional commitment takes NATCO's total investment in the US xenotransplantation company to $24.7 million.
The Delhi startup's antibody-drug conjugate targets liver and gastrointestinal cancers; the Tyagi family office led the round.
The Hyderabad injectables maker will partner with group company Fosun Pharma USA in a new US entity; the deal is expected to close by 31 October.
The generic version of Fycompa will be made at APL Healthcare's Unit-IV and targets a US market estimated at $67 million.
Get breaking health news alerts instantly — no spam.
AI assistant for news & information only — not medical advice. Emergency? Call 108 / 112.